Epidermolysis Bullosa - Pipeline Review, H1 2016

Date: April 27, 2016
Pages: 80
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E3141EB44B4EN
Leaflet:

Download PDF Leaflet

Epidermolysis Bullosa - Pipeline Review, H1 2016
Epidermolysis Bullosa - Pipeline Review, H1 2016

SUMMARY

Global Markets Direct’s, ‘Epidermolysis Bullosa - Pipeline Review, H1 2016’, provides an overview of the Epidermolysis Bullosa pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa
  • The report reviews pipeline therapeutics for Epidermolysis Bullosa by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Epidermolysis Bullosa therapeutics and enlists all their major and minor projects
  • The report assesses Epidermolysis Bullosa therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Epidermolysis Bullosa
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Epidermolysis Bullosa pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Epidermolysis Bullosa Overview
Therapeutics Development
Pipeline Products for Epidermolysis Bullosa - Overview
Pipeline Products for Epidermolysis Bullosa - Comparative Analysis
Epidermolysis Bullosa - Therapeutics under Development by Companies
Epidermolysis Bullosa - Therapeutics under Investigation by Universities/Institutes
Epidermolysis Bullosa - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Epidermolysis Bullosa - Products under Development by Companies
Epidermolysis Bullosa - Products under Investigation by Universities/Institutes
Epidermolysis Bullosa - Companies Involved in Therapeutics Development
Birken AG
Fibrocell Science, Inc.
GlaxoSmithKline Plc
InMed Pharmaceuticals Inc.
Karus Therapeutics Limited
ProQR Therapeutics N.V.
RegeneRx Biopharmaceuticals, Inc.
Scioderm, Inc.
Stratatech Corporation
TWi Pharmaceuticals, Inc.
WAVE Life Sciences Ltd.
Epidermolysis Bullosa - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
allantoin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALLO-ASC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide 1 to Inhibit Keratin for Epidermolysis Bullosa Simplex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide 2 to Inhibit Keratin for Epidermolysis Bullosa Simplex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biologic for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
birch bark extract - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Dermatology and Immunology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diacerein - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate Lysyl Hydroxylase-3 for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GMHDFCOL-7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ICX-RHY - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INM-750 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KA-1463 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QRX-313 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RGN-137 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epidermolysis Bullosa - Recent Pipeline Updates
Epidermolysis Bullosa - Dormant Projects
Epidermolysis Bullosa - Discontinued Products
Epidermolysis Bullosa - Product Development Milestones
Featured News & Press Releases
Dec 04, 2015: RegeneRx Receives Chinese Patent for Key TB4 Peptide Fragment
Nov 04, 2015: InMed Provides Update on Progress of its Development Program for Epidermolysis Bullosa
Oct 08, 2015: Fibrocell and Intrexon Announce Poster Presentation on FCX-007 for the Treatment of RDEB at American Society of Human Genetics Annual Meeting
Sep 25, 2015: Fibrocell and Intrexon Provide Regulatory Update for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
Sep 02, 2015: InMed Commences Development of Proprietary Drug Delivery System
Aug 06, 2015: InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis bullosa simplex
Jul 22, 2015: RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment
Jul 20, 2015: Fibrocell and Intrexon Announce IND Filing of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
Jul 14, 2015: Scioderm to Submit Rolling NDA to U.S. FDA for Zorblisa
Jun 08, 2015: Fibrocell and Intrexon Announce Positive in vitro Pre-Clinical Data for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) at European Society of Human Genetics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Epidermolysis Bullosa, H1 2016
Number of Products under Development for Epidermolysis Bullosa - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Epidermolysis Bullosa - Pipeline by Birken AG, H1 2016
Epidermolysis Bullosa - Pipeline by Fibrocell Science, Inc., H1 2016
Epidermolysis Bullosa - Pipeline by GlaxoSmithKline Plc, H1 2016
Epidermolysis Bullosa - Pipeline by InMed Pharmaceuticals Inc., H1 2016
Epidermolysis Bullosa - Pipeline by Karus Therapeutics Limited, H1 2016
Epidermolysis Bullosa - Pipeline by ProQR Therapeutics N.V., H1 2016
Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016
Epidermolysis Bullosa - Pipeline by Scioderm, Inc., H1 2016
Epidermolysis Bullosa - Pipeline by Stratatech Corporation, H1 2016
Epidermolysis Bullosa - Pipeline by TWi Pharmaceuticals, Inc., H1 2016
Epidermolysis Bullosa - Pipeline by WAVE Life Sciences Ltd., H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Epidermolysis Bullosa Therapeutics - Recent Pipeline Updates, H1 2016
Epidermolysis Bullosa - Dormant Projects, H1 2016
Epidermolysis Bullosa - Discontinued Products, H1 2016

LIST OF FIGURES

Number of Products under Development for Epidermolysis Bullosa, H1 2016
Number of Products under Development for Epidermolysis Bullosa - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

COMPANIES MENTIONED

Birken AG
Fibrocell Science, Inc.
GlaxoSmithKline Plc
InMed Pharmaceuticals Inc.
Karus Therapeutics Limited
ProQR Therapeutics N.V.
RegeneRx Biopharmaceuticals, Inc.
Scioderm, Inc.
Stratatech Corporation
TWi Pharmaceuticals, Inc.
WAVE Life Sciences Ltd.
Skip to top


Ask Your Question

Epidermolysis Bullosa - Pipeline Review, H1 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: